Ins bankrupt DNA take a look at corporate 23andme is to be bought by way of Regeneron

Companies said on Monday that drug manufacturer Reagenron Pharmaceuticals would buy genetic testing firm 23andme $ 256 million through a bankrupt auction for USD $ 256 million.

Regenronon said that this customer would comply with the use of data 23andme’s privacy policies and applied laws and it is ready to expand its intended use of data to the oversier appointed by the court.

The bankruptcy proceedings filed in March investigated the MPs, who warned that the genetic data of millions of customers could be sold to dishonest buyers.

23andme agreed to allow customers’ genetic information and its safety policies to handle the company to operate the company appointed by the court during bankruptcy last month.

The company has collected genetic data from 15 million customers who ordered their DNA test kit online and offered saliva samples.

The company was struggling with its ancestor test kit and a weak demand for a data violation in 2023, exposing the genetic data of millions of customers.

As part of the agreement, Regoronon will acquire all the 23andme units, except the telehland service Lamad Health, which the genetic testing firm plans to fly down.

After the completion of the transaction, the 23andme will continue to work as a direct or indirect unit of Rejoronon, the companies said.

Companies are expected to close the deal in the third quarter of this year.